STOCK TITAN

Allogene Therapeutics Inc - ALLO STOCK NEWS

Welcome to our dedicated news page for Allogene Therapeutics (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Allogene Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Allogene Therapeutics's position in the market.

Rhea-AI Summary
Allogene Therapeutics, Inc. (ALLO) announces restatement of financial statements due to non-cash accounting adjustments, with no impact on cash, cash equivalents, or marketable investments. The company targets filing amended financial statements by March 14, 2024, and reaffirms financial stability until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
Rhea-AI Summary
Allogene Therapeutics, Inc. (ALLO) will participate in three upcoming investor conferences in January and February. The company is a clinical-stage biotechnology firm focused on allogeneic CAR T products for cancer and autoimmune disease. The webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences
-
Rhea-AI Summary
Allogene Therapeutics Inc. (ALLO) and Foresight Diagnostics partner to utilize Foresight’s ultra-sensitive MRD technology for the ALPHA3 trial, aiming to identify patients for first-line consolidation treatment of large B-cell lymphoma. The partnership will develop an in-vitro diagnostic to determine eligibility for the trial, using Foresight’s PhasED-Seq ctDNA-MRD platform. The study will assess whether patients benefit from consolidation with cema-cel, potentially changing the 1L treatment plan for newly diagnosed LBCL patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.86%
Tags
partnership
Rhea-AI Summary
Allogene Therapeutics, Inc. (ALLO) announces its 2024 Platform Vision, focusing on groundbreaking trials for allogeneic CAR T products in large B-cell lymphoma, chronic lymphocytic leukemia, autoimmune disease, and renal cell carcinoma. The company aims to redefine CAR T development and trial design, potentially revolutionizing the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.86%
Tags
none
-
Rhea-AI Summary
Allogene Therapeutics, Inc. (ALLO) announced a conference call to preview its 2024 Platform Vision focused on redefining the future of CAR T by leveraging the unique attributes of allogeneic CAR T products. David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene, will present the 2024 Platform Vision at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences
-
Rhea-AI Summary
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced positive results from the Phase 1 ALPHA/ALPHA2 trials for ALLO-647, demonstrating its potential to yield durable responses and a safety profile comparable to approved autologous CAR T therapies. The company also received Fast Track Designation for ALLO-647 for use in adult patients with relapsed/refractory Large B-Cell Lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will participate in the JMP Securities Hematology and Oncology Summit on December 6, 2023, to showcase its allogeneic CAR T (AlloCAR T™) products for cancer. The webcast will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
none
-
Rhea-AI Summary
Allogene Therapeutics presented preclinical data on their AlloCAR T product candidate targeting Claudin18.2-positive gastric and pancreatic tumors. The data showed potent activity in vitro and in vivo, suggesting the potential for clinical benefit with a single off-the-shelf infusion. ALLO-182, the lead candidate, is currently in the IND-enabling phase of development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
clinical trial
-
Rhea-AI Summary
Allogene Therapeutics presented data on their Cloak and Dagger technologies at the SITC Annual Meeting. These technologies aim to enhance the performance of AlloCAR T cell candidates by reducing rejection by the immune system. The Cloak technology prevents recognition by host T cells, while the Dagger technology enables dual specificity against CD70-positive host immune cells and CD19-positive tumor cells. These advancements have the potential to make CAR T therapies more scalable and accessible to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
clinical trial
Rhea-AI Summary
Allogene Therapeutics, Inc. provided a corporate update and reported financial results for Q3 2023. They ended the quarter with $497.7 million in cash, cash equivalents, and investments. The company expects a decrease in cash of approximately $230 million in 2023, with a cash runway projected into the second half of 2025. They announced preclinical posters to be presented at upcoming conferences, highlighting the potential of their AlloCAR T platform and providing updates on their clinical trials for ALLO-501A and ALLO-647. The company also announced appointments to its leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.85%
Tags
earnings
Allogene Therapeutics Inc

Nasdaq:ALLO

ALLO Rankings

ALLO Stock Data

779.12M
109.32M
22.11%
74.3%
13.72%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
South San Francisco

About ALLO

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le